CD4 and neoplasm: “Professional” APCs and other MHC II-expressing tumor cells contribute to the initiation and maintenance of anti-tumor immunity through interaction with tumor-specific CD4+ T cells (Harryvan et al., 2021; Tay et al., 2021).